Axonics initiated with a Buy at Mizuho

Mizuho initiated coverage of Axonics with a Buy rating and $75 price target. The Buy rating is based positive feedback from an incontinence survey, which suggests same-store implant growth of 20% for the U.S. sacral neuromodulation market, potentially above expectations, the analyst tells investors in a research note. The firm believes Axonics’ products will maintain a competitive standing in incontinence.